You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205011 - 205020 of 207712 results
  1. SUBCUTANEOUS MONITOR/ALARM FOR CARDIAC ARREST

    SBC: AJ MEDICAL DEVICES, INC.            Topic: N/A

    It is estimated that 220,000 people suffer cardiac arrest each year in the US, of whom only 10,000 survive to hospital discharge. The number of survivors could increase 10-fold if paramedical attention and/or defibrillation were available within a few min

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma

    SBC: VIEWPOINT MOLECULAR TARGETING, INC.            Topic: 102

    SIGNIFICANCE: Melanoma incidence is rising faster than any other cancer and metastatic melanoma is typically fatal. Responses to targeted and immunotherapies can be remarkable, but low response rates, acquired resistance, and adverse side effects limit long-term quality of life for these patients. The overall response rate to all therapies remains dismally near 50% and the 5-year survival is andlt ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Genital Herpes Vaccine Discovery

    SBC: MOLECULAR EXPRESS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The primary objective of this project is to develop, using a novel vaccine platform technology (the VesiVax(r) system), a safe HSV2 vaccine that is capable of providing a level of protection in male and female human pop ulations which is better than other recombinant vaccines. We have shown that HSV2 VesiVax(r) vaccines targeted to single epitopes from the gD e ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  4. PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.

    SBC: Biomarker Strategies, LLC            Topic: 102

    Lung cancerLCis the leading cause of cancer death in the US with an estimateddeaths inNonsmall cell LC is the predominant category of the diseaseNSCLCMolecular characterization of tumors has shifted the paradigm of one drug fits allCurrentlymolecularly targeted agentsMTAsand companion diagnosticsCDxare being developed to target oncogenic drivers in signaling pathwaysand select patients most likely ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Orthogonal Approach to Malware Detection and Classification

    SBC: MAYACHITRA, INC.            Topic: N151067

    Today's commercial Antivirus defense mechanisms are based on scanning systems for suspicious activity. If such an activity is found, the suspect files are either quarantined or the vulnerable system is patched with an update. In turn, the Antivirus software are also updated with new signatures to identify such activities in future. Such scanning methods are based on a variety of techniques such as ...

    SBIR Phase II 2017 Department of DefenseNavy
  6. A modular platform for infectious disease surveillance at point-of-need.

    SBC: Redbud Labs, Inc.            Topic: NIAID

    ABSTRACT We propose to develop a point-of-need system for differential molecular identification of filoviruses from syndromically similar infections. Our goal is to enable rapid, sensitive, and specific identification of quarantinable infections to reduce nosocomial risk and improve outbreak response. The platform will simultaneously test 12 genomic markers at the genus and strain level using a mo ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical Development of Non-compressible Hemostatic Agent for High-Volume Hemorrhage

    SBC: BIOMEDICA MANAGEMENT CORP.            Topic: NHLBI

    DESCRIPTION provided by applicant andquot ClotFoam R andquot is a novel adhesive sealant composition and second generation hemostatic agent This biological agent was designed to arrest moderate to severe blood loss arising from intracavitary traumatic injury or intraoperative hemorrhage without compression stitches or staples Control of Intraoperative hemorrhage in laparoscopic surgery whi ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes

    SBC: INTACT GENOMICS INC            Topic: NIAID

    PROJECT SUMMARY. The economic and social burden of the treatment of infectious and chronic diseases is enormous, rt$300B annually. The ongoing COVID-19 pandemic alone will cost the U.S. economy roughly $8 trillion over the next decade without an effective drug to date. The emergence of drug resistant microbes, the diminishing supply of novel classes of antibiotics, and the dramatic reduction in Ra ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTNon-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases related to metabolic syndrome that are characterized by steatosis, the accumulation of fat within the liver. Non-alcoholic steatohepatitis (NASH), the most aggressive NAFLD subtype, refers to the presence of inflammation and necrosis in a background of steatosis, and is associated with hepatic fibrosis. NASH is a se ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A Web Service for Fragment-based Selectivity Analysis of Drug Leads

    SBC: CONIFER POINT PHARMACEUTICALS LLC            Topic: 400

    Significance: The goal of selective drug binding is a fundamental objective in the discovery and optimization of a compound on a trajectory toward helping patients and becoming an approved medication. To aid in this goal, our proposal aims to commercialize an innovative tool that addresses target selectivity in a rational de- sign methodology. The prototype tool leverages our large database of che ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government